Literature DB >> 24819904

Usefulness of left ventricular diastolic function to predict recurrence of atrial fibrillation in patients with preserved left ventricular systolic function.

Taishi Hirai1, George Cotseones1, Nader Makki2, Anoop Agrawal3, David J Wilber3, John T Barron4.   

Abstract

It is unknown whether recurrence of atrial fibrillation (AF) is related to severity of left ventricular diastolic dysfunction (LVDD) before ablation in patients with preserved left ventricular ejection fraction (LVEF). We tested the hypothesis that the presence and/or severity of LVDD before catheter ablation are related to AF recurrence during the 12-month follow-up period in patients with normal LVEF. We also aimed to determine what echocardiographic and Doppler indexes of LVDD before ablation are associated with recurrence of AF after ablation. We identified 198 patients with normal LVEF who underwent catheter ablation for AF with evidence of normal sinus rhythm within 1 year before ablation. The recurrence rate during 12-month follow-up period was assessed. Of the 198 patients, 76 patients (38%) had symptomatic recurrence and 122 patients (62%) had no recurrence. None of the independent variables, including mitral valve Doppler E and A peak velocities, E/A ratio, tissue Doppler e' and a' peak velocities, left atrial volume index, isovolumic relaxation time, and deceleration time, predicted recurrence. Patients with average E/e' ratio >13, however, had increased recurrence (67% vs 35%, odds ratio 3.70, 95% confidence interval 1.21 to 11.3, p <0.05). In conclusion, there was no difference in the severity of LVDD using conventional echocardiographic indexes of LVDD in patients with or without recurrence of AF ablation. However, patients with average E/e' ratio >13 did have an increased recurrence rate of AF at 12 months after procedure. Therefore, E/e' ratio, indicative of increased left atrial pressure, may serve as a marker for AF recurrence after ablation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24819904     DOI: 10.1016/j.amjcard.2014.03.061

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Clinical Relevance of the Spectral Tissue Doppler E/e' Ratio in the Management of Patients with Atrial Fibrillation: a Comprehensive Review of the Literature.

Authors:  Stephane Arques
Journal:  J Atr Fibrillation       Date:  2018-08-31

2.  Echocardiographic predictors of atrial fibrillation recurrence after catheter ablation: A literature review.

Authors:  Aleksandra Liżewska-Springer; Alicja Dąbrowska-Kugacka; Ewa Lewicka; Łukasz Drelich; Tomasz Królak; Grzegorz Raczak
Journal:  Cardiol J       Date:  2018-06-20       Impact factor: 2.737

3.  Increased left atrial pressure predicts recurrence following successful cryoablation for atrial fibrillation with second-generation cryoballoon.

Authors:  Banu Evranos; Duygu Kocyigit; Kadri Murat Gurses; Muhammed Ulvi Yalcin; Mehmet Levent Sahiner; Ergun Baris Kaya; Necla Ozer; Kudret Aytemir
Journal:  J Interv Card Electrophysiol       Date:  2016-01-29       Impact factor: 1.900

4.  Relationship between exercise induced elevation of left ventricular filling pressure and exercise intolerance in patients with atrial fibrillation.

Authors:  Shao-Min Chen; Rong He; Wei-Hong Li; Zhao-Ping Li; Bao-Xia Chen; Xin-Heng Feng
Journal:  J Geriatr Cardiol       Date:  2016-09       Impact factor: 3.327

5.  Value of dual Doppler echocardiography for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation.

Authors:  Fengjiao Chen; Qinliang Sun; Hairu Li; Shaohui Qu; Weidong Yu; Shuangquan Jiang; Jiawei Tian
Journal:  BMC Cardiovasc Disord       Date:  2019-11-15       Impact factor: 2.298

Review 6.  Heart failure with preserved ejection fraction based on aging and comorbidities.

Authors:  Ying Lin; Shihui Fu; Yao Yao; Yulong Li; Yali Zhao; Leiming Luo
Journal:  J Transl Med       Date:  2021-07-06       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.